Table 2

Laboratory measures in the presence or absence of any thrombosis (venous or arterial)

All cohort
% (n/N)
Absence of thrombosis
% (n/N)
Presence of thrombosis
% (n/N)
Positive
LR
(95% CI)
Negative
LR
(95% CI)
OR (95% CI)
Anti-dsDNA >35 U29.5 (44/149)27.1 (36/133)50.0 (8/16)1.85 (0.98 to 3.1)0.69 (0.38 to 1.01)2.69 (0.97 to 7.62)
Low C3 (<81 mg/dL)*11.5 (17/148)7.6 (10/132)43.7 (7/16)5.78 (2.49 to 12.38)0.61 (0.36 to 0.84)9.49 (3.01 to 30.26)§
Low C4 (<12.9 mg/dL)16.9 (25/148)14.4 (19/132)37.5 (6/16)2.61 (1.16 to 5.13)0.73 (0.45 to 0.97)3.57 (1.20 to 10.70)§
EC4d >14 net MFI33.6 (50/149)30.1 (40/133)62.5 (10/16)2.08 (1.22 to 3.10)0.54 (0.26 to 0.89)3.88 (1.36 to 11.03)§
BC4d >60 net MFI†27.7 (39/141)26.2 (33/126)40.0 (6/15)1.53 (0.72 to 2.74)0.81 (0.48 to 1.12)1.87 (0.64 to 5.51)
PC4d >20 net MFI21.5 (32/149)16.5 (22/133)62.5 (10/16)3.78 (2.08 to 6.22)0.45 (0.22 to 0.74)8.41 (2.84 to 24.78)§
LAC, dRVVT >37 s‡59.7 (86/144)56.3 (72/128)87.5 (14/16)1.56 (1.11 to 1.91)0.29 (0.08 to 0.84)5.44 (1.31 to 22.34)§
Anticardiolipin IgM (≥20 U)6.7 (10/149)6.8 (9/133)6.3 (1/16)0.92 (0.15 to 4.82)1.01 (0.76 to 1.10)0.92 (0.14 to 6.17)
Anticardiolipin IgG (≥20 U)16.1 (24/149)15.8 (21/133)18.8 (3/16)1.19 (0.39 to 3.04)0.96 (0.67 to 1.14)1.23 (0.35 to 4.44)
Anticardiolipin IgA (≥20 U)15.4 (23/149)13.5 (18/133)31.3 (5/16)2.31 (0.95 to 4.89)0.79 (0.51 to 1.01)2.90 (0.94 to 9.07)
Antibeta2 GP1 IgM (≥20 U)2.7 (4/149)2.3 (3/133)6.3 (1/16)2.77 (0.40 to 17.6)0.96 (0.73 to 1.03)2.89 (0.39 to 22.11)
Antibeta2 GP1 IgG (≥20 U)22.1 (33/149)21.1 (28/133)31.3 (5/16)1.48 (0.64 to 2.96)0.87 (0.56 to 1.11)1.70 (0.57 to 5.14)
Antibeta2 GP1 IgA (≥20 U)8.1 (12/149)6.8 (9/133)18.8 (3/16)2.77 (0.84 to 8.08)0.87 (0.61 to 1.01)3.18 (0.93 to 12.50)
Anti-PS/PT IgM (>30 U)36.9 (55/149)34.6 (46/133)56.3 (9/16)1.63 (0.92 to 2.46)0.67 (0.35 to 1.05)2.43 (0.87 to 6.76)
Anti-PS/PT IgG (>30 U)21.5 (32/149)16.5 (22/133)62.5 (10/16)2.22 (1.16 to 3.70)0.64 (0.36 to 0.95)3.43 (1.22 to 9.67)§
  • LR and OR are given with 95% CI.

  • *C3 was not available in one patient.

  • †BC4d was not available in 8 patients due to low number of events.

  • ‡LAC was not available in 4 patients.

  • §P<0.05.

  • BC4d, B lymphocytes C4d; EC4d, erythrocyte C4d; GP1, glycoprotein 1; LAC, lupus anticoagulant; LR, likelihood ratio; MFI, mean fluorescence intensity; PC4d, platelets C4d; PS/PT, phosphatidyl serine/prothrombin; anti-dsDNA, antidouble-stranded DNA; dRVVT, dilute Russell’s viper venom time.